SOUTH SAN FRANCISCO, Calif.,
April 12, 2018 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), reported
that due to an error by the external host of its investor relations
website, inaccurate information was displayed regarding the U.S.
Food and Drug Administration's (FDA) review of the New Drug
Application (NDA) for fostamatinib for the treatment of adult
patients with chronic immune thrombocytopenia (ITP). The
website has been corrected. The FDA is continuing its review
of the NDA and the Prescription Drug User Fee Act (PDUFA) action
date is April 17, 2018.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc., is a biotechnology company
dedicated to discovering, developing and providing novel small
molecule drugs that significantly improve the lives of patients
with immune and hematologic disorders, cancer and rare
diseases. Rigel's pioneering research focuses on signaling
pathways that are critical to disease mechanisms. The company's
current programs include clinical studies of fostamatinib, an oral
spleen tyrosine kinase (SYK) inhibitor, in a number of indications.
Rigel has an NDA under review with the FDA for
fostamatinib in patients with chronic immune thrombocytopenia
(ITP). In addition, Rigel has product candidates in development
with partners BerGenBio AS, Daiichi
Sankyo and Aclaris Therapeutics.
Forward Looking Statements
This release contains forward-looking statements relating to,
among other things, the information displayed on its website and
its current clinical trials and those programs which are
partnered. Any statements contained in this press release that
are not statements of historical fact may be deemed to be
forward-looking statements. Words such as "planned," "will," "may,"
"should," "expect," and similar expressions are intended to
identify these forward-looking statements. These forward-looking
statements are based on Rigel's current expectations and inherently
involve significant risks and uncertainties. Actual results and the
timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, the timing,
completion and results of clinical trials; market competition; as
well as other risks detailed from time to time in Rigel's reports
filed with the Securities and Exchange Commission, including
its Quarterly Report on Form 10-K for the period
ended December 31, 2017. Rigel does not undertake any
obligation to update forward-looking statements and expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein.
Contact: Raul Rodriguez
Phone: 650.624.1302
Email: ir@rigel.com
Media Contact: David Polk
Phone: 310.309.1029
Email: david.polk@syneoshealth.com
Logo -
http://photos.prnewswire.com/prnh/20030226/RIGLLOGO
View original content with
multimedia:http://www.prnewswire.com/news-releases/rigel-makes-statement-regarding-website-error-300629259.html
SOURCE Rigel Pharmaceuticals, Inc.